EGFR and non-small cell lung carcinoma: Osimertinib is now also an FDA-approved drug for the first-line treatment of advanced NSCLCs with EGFR activating mutations in addition to its application as a second-line treatment of EGFR mutant (EGFRm) NSCLC patients relapsed from first generation EGFR-TKIs due to T790M mutation.